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Abstract: Background: The cognitive impairments that characterize Down syndrome (DS) have
been attributed to brain hypocellularity due to neurogenesis impairment during fetal
stages. Thus, enhancing prenatal neurogenesis in DS could prevent or reduce some of
the neuromorphological and cognitive defects found in post-natal stages.Objectives:
Because fatty acids play a fundamental role in morphogenesis and brain development
during fetal stages, in this study, we aimed to enhance neurogenesis and the cognitive
abilities of the Ts65Dn (TS) mouse model of DS by administering oleic or linolenic
acid.Methods: Eighty-five pregnant TS females were subcutaneously treated from
embryonic day (ED) 10 until postnatal day (PD) 2 with oleic acid (400 mg/kg), linolenic
acid (500 mg/kg), or vehicle. All analyses were performed on their TS and Control (CO)
male and female progeny. At PD2, we evaluated the short-term effects of the
treatments on neurogenesis, cellularity, and brain weight, in 40 TS and CO pups. Sixty-
nine TS and CO mice were used to test the long-term effects of the prenatal treatments
on cognition from PD30 to PD45, and on neurogenesis, cellularity, and synaptic
markers, at PD45. Data were compared by ANOVAs.Results: Prenatal administration
of oleic or linolenic acid increased the brain weight (+36.7% and +45%, P<0.01), the
density of BrdU- (Bromodeoxyuridine) (+80% and +115%; P<0.01), and DAPI (4′,6-
diamidino-2-phenylindole)-positive cells (+64% and +22%, P<0.05) of PD2 TS mice
with respect to the vehicle-treated TS mice. Between PD30 and PD45, TS mice
prenatally-treated with oleic or linolenic acid showed better cognitive abilities (+28%
and +25%, P<0.01) and a higher density of the post-synaptic marker PSD95
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
(Postsynaptic Density Protein 95) (+65% and +44%, P<0.05) than the vehicle-treated
TS animals.Conclusion: The beneficial cognitive and neuromorphological effects
induced by oleic or linolenic acid in TS mice suggest that they could be promising
pharmacotherapies for DS-associated cognitive deficits.
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Background: The cognitive impairments that characterize Down syndrome (DS) 2 
have been attributed to brain hypocellularity due to neurogenesis impairment during 3 
fetal stages. Thus, enhancing prenatal neurogenesis in DS could prevent or reduce 4 
some of the neuromorphological and cognitive defects found in post-natal stages. 5 
Objectives: Because fatty acids play a fundamental role in morphogenesis and 6 
brain development during fetal stages, in this study, we aimed to enhance 7 
neurogenesis and the cognitive abilities of the Ts65Dn (TS) mouse model of DS by 8 
administering oleic or linolenic acid.  9 
Methods: Eighty-five pregnant TS females were subcutaneously treated from 10 
embryonic day (ED) 10 until postnatal day (PD) 2 with oleic acid (400 mg/kg), 11 
linolenic acid (500 mg/kg), or vehicle. All analyses were performed on their TS and 12 
Control (CO) male and female progeny. At PD2, we evaluated the short-term 13 
effects of the treatments on neurogenesis, cellularity, and brain weight, in 40 TS 14 
and CO pups. Sixty-nine TS and CO mice were used to test the long-term effects of 15 
the prenatal treatments on cognition from PD30 to PD45, and on neurogenesis, 16 
cellularity, and synaptic markers, at PD45. Data were compared by ANOVAs. 17 
Results: Prenatal administration of oleic or linolenic acid increased the brain weight 18 
(+36.7% and +45%, P<0.01), the density of BrdU- (Bromodeoxyuridine) (+80% and 19 
+115%; P<0.01), and DAPI (4′,6-diamidino-2-phenylindole)-positive cells (+64% 20 
and +22%, P<0.05) of PD2 TS mice with respect to the vehicle-treated TS mice. 21 
Between PD30 and PD45, TS mice prenatally-treated with oleic or linolenic acid 22 
showed better cognitive abilities (+28% and +25%, P<0.01) and a higher density of 23 
the post-synaptic marker PSD95 (Postsynaptic Density Protein 95) (+65% and 24 
+44%, P<0.05) than the vehicle-treated TS animals.  25 
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Conclusion: The beneficial cognitive and neuromorphological effects induced by 26 
oleic or linolenic acid in TS mice suggest that they could be promising 27 
pharmacotherapies for DS-associated cognitive deficits. 28 
Keywords: Down syndrome; Ts65Dn mice; oleic acid; linolenic acid; prenatal 29 




LAY SUMMARY 32 
Down syndrome (DS) is characterized by cognitive dysfunction due to alterations in 33 
neurogenesis during prenatal stages. Because linolenic and oleic acid increase 34 
neurogenesis in these stages, its administration could improve the cognitive abilities of 35 
DS individuals. We aimed to test whether prenatal administration of these acids could 36 
restore the brain alterations (i.e. neurogenesis and cellularity) and the cognitive 37 
impairments in the Ts65Dn (TS) mouse model of DS. We treated pregnant TS females 38 
with oleic acid, linolenic acid or vehicle and we analyzed neurogenesis and cellularity in 39 
their newborn pups. TS pups that received prenatally oleic or linolenic acid presented 40 
higher neurogenesis and cellularity than those that received vehicle. To determine 41 
whether these prenatal treatments had long-term effects on cognition, neurogenesis 42 
and the number of synapses, another group of mice whose mothers received oleic 43 
acid, linolenic acid or vehicle during gestation was used. At the age of 4-6 weeks, TS 44 
mice that received prenatally oleic or linolenic acid presented better cognitive abilities 45 
and a higher density of synapses than TS mice treated prenatally with vehicle. The 46 
beneficial effects observed in TS mice suggest that oleic acid and linolenic acid could 47 






Down syndrome (DS), the most common genetic cause of intellectual disability, is 52 
characterized by numerous neurobiological alterations. One of the factors partially 53 
responsible for the cognitive impairments in DS is the brain hypocellularity due to 54 
alterations in neurogenesis during the early developmental stages (1-4).  55 
The Ts65Dn (TS) mouse, the most commonly used DS model, resembles many of its 56 
phenotypes exhibiting altered cognitive abilities, hypocellularity, and reduced 57 
neurogenesis (4, 5-7). Thus, therapies aimed at rescuing neurogenesis might be a 58 
good approach to treating intellectual disability in DS individuals. Several 59 
pharmacotherapies have been reported to rescue the neurogenesis and cognitive 60 
deficits in DS murine models when administered in the pre- or post-natal stages (8-20). 61 
However, some of these drugs have failed to produce any benefit in humans or cannot 62 
be safely administered to individuals with DS. In addition, DS individuals and TS mice 63 
present altered development of the brain, beginning at the fetal stages (2, 3, 21). 64 
Therefore, these alterations should be corrected from the early developmental stages, 65 
using safe drugs or natural substances that can be administered during the prenatal or 66 
early postnatal stages (2, 10, 11, 22).  In this context, the administration of fatty acids 67 
could be a promising strategy. 68 
There is a direct association between the percentage of fatty acids in maternal plasma 69 
and the development of cognitive function in neonates (23), and exogenous 70 
administration of fatty acids during the pre- and post-natal periods increases brain 71 
development in humans and other animals (24). Oleic acid is a monounsaturated acid 72 
of the omega-9 series. It is present endogenously in the organism and it can also be 73 
obtained from the diet. Oleic acid acts as a neurotrophic factor in initial life stages, 74 
inducing neuronal differentiation, the growth of new neurites, neuronal migration, and 75 
synapse formation (25-30). 76 
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α-Linolenic acid is an essential Polyunsaturated Fatty Acid (PUFA) of the omega-3 77 
series, which has to be obtained from the diet. Linolenic acid is essential for proper 78 
brain development; its deficit can affect neurogenesis and neuronal function (31-33). In 79 
rodents, supplementation of linolenic acid or its derivative Docosahexaenoic Acid 80 
(DHA) in the diet of pregnant females enhances cognition and neurogenesis in the 81 
brains of their offspring (32-51).  82 
In DS, the lower levels of fatty acids in brain phospholipids (52), could be partially 83 
responsible for some of the neuromorphological and cognitive alterations encountered 84 
in this syndrome. Thus, treatment with fatty acids during the critical windows of 85 
neurogenesis (the prenatal and early postnatal periods) may induce beneficial effects. 86 
In addition, oleic acid and linolenic acid do not produce important side effects, and their 87 
efficacy in treating different pathologies is currently being evaluated (53-55). Thus, the 88 
aim of this study was to analyze whether prenatal administration of oleic or linolenic 89 
acid restores the neuromorphological alterations found in TS mice, and whether these 90 
effects are maintained after discontinuation of the treatment, leading to enhanced 91 






Animals, Diets and Treatments 96 
This study was approved by the Cantabria University Institutional Laboratory Animal 97 
Care and Use Committee and performed in accordance with the Declaration of Helsinki 98 
and the European Communities Council Directive (86/609/EEC). 99 
TS mice were generated by repeated backcrossing of B6EiC3Sn a/A-Ts(17<16>)65Dn 100 
females with C57BL/6Ei × C3H/HeSNJ (B6EiCSn) F1 hybrid males. TS mice were 101 
compared with euploid littermates (Control, CO). Trisomy was determined by real-time 102 
qPCR (quantitative Polymerase Chain Reaction) as previously described (56).  103 
Diet 104 
All pregnant and lactating TS mice were fed with Tekcal 18% protein (#2018, 105 
containing 18.6% raw protein, 6.2% fat and 44.2% carbohydrates) Global Mouse 106 
Chow, specially formulated for gestation and lactation (INVIGO, Huntingdon, UK), from 107 
ED (Embryonic Day) 0 until the weaning of the pups. For the study of the long-term 108 
effects, all TS and CO mice received Tekcal Mouse Chow 14% protein (#2014, 109 
INVIGO, containing 14.3 % raw protein, 4.0% fat and 48.0% carbohydrates), designed 110 
to promote normal body weight and longevity in the rodents from weaning (Postnatal 111 
Day (PD) 21) to the end of the study.  112 
Treatments 113 
A total of eighty-five pregnant TS females were subcutaneously treated with oleic acid 114 
(400 mg/kg), linolenic acid (500 mg/kg), or vehicle (Bovine Serum Albumin (BSA) 10 115 
%) from ED10 until PD2). The doses selected are neuroprotective and/or induce 116 
neurogenesis (35, 47, 57, 58). Plasma concentrations of the three compounds in the 117 
PD2 pups were quantified by High-Performance Liquid Chromatography (HPLC). Male 118 
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and female TS and CO pups gestated by forty-five TS females under the different 119 
treatments were used for the study of the short-term effects, and TS and CO mice of 120 
both sexes gestated by 40 dams under the three treatment conditions were used for 121 
the long-term effects study. All the experimental analyses were performed on the 122 
progeny of the pregnant-treated TS mice.  123 
The offspring of these females were assigned to the one of the six experimental groups 124 
depending on their karyotype and the prenatal treatment that they received: CO pups 125 
that were treated prenatally with vehicle (CO-V), oleic acid (CO-OA), or linolenic acid 126 
(CO-LNA), and TS pups that prenatally received vehicle (TS-V), oleic acid (TS-OA), or 127 
linolenic acid (TS-LNA). For the long-term effects study, sixty-nine male and female TS 128 
and CO pups gestated by dams under the three treatments were assigned to the same 129 
experimental groups. Six to seven pups from each group were used to evaluate the 130 
short-term effects (i.e. neurogenesis, cellularity, and brain volume), and 10-13 juvenile 131 
mice prenatally treated with oleic acid, linolenic acid, or vehicle (n=10-13 per group; 132 
CO-V: n=10, TS-V: n=13, CO-OA: n=12, TS-OA: n=10, CO-LNA: n=12, TS-LNA n=12), 133 
were used to assess the long-term effects of the treatments (i.e. cognition in the Morris 134 
water maze (MWM), neurogenesis, cellularity, and pre- and post-synaptic markers). 135 
Short-term effects of prenatal treatment 136 
To evaluate the short-term effects of oleic and linolenic acid on cell proliferation, on 137 
PD2, all pups received an intraperitoneal injection of Bromodeoxyuridine (BrdU) (150 138 
µm/g). Two hours later, they were weighed, euthanized by decapitation, and their 139 
brains were removed, weighed and fixed in paraformaldehyde (PFA) solution, 140 
transferred to 30% sucrose and frozen at -80° C.  Coronal sections of 30 µm covering 141 
the whole hippocampus were cryosectioned, and stored at -20° C. From each animal 7 142 
series containing 6-8 hippocampal sections were obtained to perform the histological 143 
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analyses: granule cell layer (GCL) volume, cell proliferation (BrdU) and granule cell 144 
density (4′,6-Diamidino-2-phenylindole, DAPI staining). 145 
Long-term effects of prenatal treatments 146 
To evaluate the long-term effects of the different treatments on new neuron survival, on 147 
PD15 all pups received an intraperitoneal injection of BrdU (150 µg/g). On PD21, all the 148 
animals were weaned and subjected to the behavioral experiments (Morris Water 149 
Maze, MWM) between PD30 and PD45. On PD45, the animals were euthanized by 150 
decapitation and the brains of 6-7 animals per group were removed, fixed with PFA and 151 
used for the following histological and immunohistochemical analyses: GCL volume, 152 
cell proliferation (Ki67 immunohistochemistry), survival (BrdU immunohistochemistry), 153 
pre- and post-synaptic density (Synaptophysin (SYN) and Postsynaptic Density Protein 154 
95 (PSD95) immunohistochemistry). To this end, free-floating 50 µm coronal sections 155 
covering the whole hippocampus were cryosectioned. Nine series, containing 6-8 156 
hippocampal sections, were obtained from each animal. 157 
Nissl Staining 158 
Morphological analysis of GCL volume was performed on 1 of 7 series, for the short-159 
term studies, and on 1 of 9 series, for the long-term studies. Nissl staining was 160 
performed as previously described (59). To calculate the GCL volume, each coronal 161 
section of the brain was photographed and the images were analyzed using ImageJ 162 
software (http://rsb.info.nih.gov/ij/). In all cases, the Cavaliery stereological method was 163 
used. 164 
Cell Proliferation (Ki67 and BrdU immunofluorescence)  165 
To quantify the short-term effect of the treatments on cell proliferation in the GCL of 166 
PD2 animals, BrdU immunohistochemistry was performed as previously described 167 
(10). The primary antibody used was an AntiBrdU at 1:100 (Santa Cruz) in PBS 168 
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(Phosphate-Buffered Saline) -TX (Triton X) 0.1% supplemented with 1% goat serum. 169 
The total number of BrdU+ cells was counted in the selected sections with Zen 2.6 170 
software in the GCL and calculated using the optical dissector method, as previously 171 
described (60). In each animal, the total number of positive cells per slice was divided 172 
by the volume of the GCL, to calculate the density of proliferating cells.  173 
For the long-term analyses of cell proliferation, the protocol described by Stagni et al. 174 
(18) was followed. The primary antibodies used were a rabbit anti-Ki67 at 1:750 175 
(Abcam, Cambridge, UK) diluted in Phosphate Buffer (PB) with 0.5% TX-100 and 0.1% 176 
BSA and an AntiBrdU at 1:100 (Santa Cruz). The total number of Ki67-positive cells or 177 
BrdU-positive cells in the selected sections was counted using an optical fluorescence 178 
microscope (Zeiss Axioskop 2 plus, 40x objective). The total number of positive cells 179 
was divided by the area of the Subgranular Zone (SGZ) (defined as the length of the 180 
SGZ multiplied by the thickness of the section) to determine the Ki67+ or BrdU+ cell 181 
density in the SGZ. The total number of Ki67+ cells and BrdU+ cells in the SGZ was 182 
calculated using the optical dissector method, as previously described (59, 60).  183 
DAPI Staining 184 
For the study of the short- and long-term effects on the number of mature cells, 185 
sections were counterstained with DAPI (Calbiochem, Billerica, MA, USA; 1:1000). In 186 
both the short and long-term analysis, cell counts were performed using a previously 187 
described physical dissector system coupled with confocal microscopy (61, 62).  188 
SYN and PSD95 Immunofluorescence 189 
For the long-term synaptic effects study, SYN and PSD95 immunohistochemistry were 190 
employed following the protocol previously described in Stagni et al. (18). The 191 
antibodies used were a mouse monoclonal anti-SYN (SY38) antibody (Millipore-192 
Biomanufacturing and Life Science Research, Billerica, MA, USA) and a rabbit 193 
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polyclonal anti-PSD95 antibody (Abcam) both diluted to 1:1000. Fluorescent images 194 
were captured by a confocal microscope (Leica SP5), using a 63x 1.4 NA objective and 195 
an 8x zoom. For each marker, four sections per animal were used comprising the 196 
entire hippocampus, and one random area in the Molecular Layer (ML) of the Dentate 197 
Gyrus (DG), CA1, and CA3 per section was measured. Image analysis was performed 198 
using the NIH ImageJ software. For each marker, the number of individual puncta 199 
exhibiting SYN or PSD95 immunoreactivity was counted in a circle with an area of 325 200 
μm2 for each image in each hippocampal field.     201 
Cognitive Analysis. Morris Water Maze (MWM) 202 
Spatial learning and memory were evaluated using a modified version of the MWM 203 
(20). Sixteen consecutive daily sessions were performed: 12 acquisition sessions 204 
(platform submerged, in eight of these, the position of the platform changed daily, while 205 
in the other four it was kept constant), followed by a probe trial and 4 cued sessions 206 
(platform visible). The computerized tracking system Anymaze (Stoelting, Wood Dale, 207 
IL, USA) was used to analyze the trajectories of the animals and record escape 208 
latency, distance traveled, and swimming speed of each animal in each trial.  209 
Statistics 210 
Shapiro–Wilk tests were used to test the normality of the data sets. Because all of them 211 
were normally distributed, parametric tests were used. The water maze data from the 212 
acquisition sessions (sessions 1-12) were analyzed using two-way Analysis of 213 
Variance (ANOVA) with Repeated Measures (RM) (‘session’ x ‘karyotype’ x ‘treatment’ 214 
or ‘trial’ x ‘karyotype’ x ‘treatment’). The rest of the data from the short-term and long-215 
term studies was analyzed using two-way (‘karyotype’ x ‘treatment’) ANOVA or RM 216 
ANOVA (‘quadrant’). The mean values of each experimental group were compared 217 
post hoc using Fisher’s LSD (Least Significant Difference) post-hoc tests. The 218 
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differences between groups were considered to be statistically significant when 219 
P<0.05. All analyses were performed using IBM SPSS (Armonk, New York, USA) for 220 
Windows version 22.0. 221 
 222 
RESULTS  223 
Short-term Effects of Prenatal Treatment 224 
1. Plasma Levels 225 
After administration of the vehicle to TS females during pregnancy, their PD2 offspring 226 
showed a mean value of 9.3 µg/mL of oleic acid, and 2.7 µg/mL of linolenic acid in 227 
plasma. The PD2 pups whose TS mothers received oleic acid from ED10 to PD2 228 
presented a mean value of 20.4 µg/mL of this fatty acid, while PD2 pups born from 229 
pregnant TS females that received linolenic acid during gestation showed a mean 230 
plasma level of 8.6 µg/mL of this acid.  231 
2. Body and Brain Weight 232 
At PD2, TS-V mice presented smaller body (p<0.05; figure 1A) and brain weights 233 
(P<0.01; figure 1B) than CO-V mice. Prenatal linolenic acid treatment increased the 234 
bodyweight of LNA-CO pups with respect to CO-V mice (P<0.001; figure 1A).  235 
Prenatal administration of oleic acid increased the brain weight of TS-OA mice at PD2 236 
with respect to TS-V pups (P<0.01). Linolenic acid administration increased the brain 237 
weight of mice of both karyotypes, as demonstrated by the significant increase 238 
observed in the TS-LNA group with respect to TS-V mice (P<0.001), and in CO-LNA 239 
when compared to CO-V pups (P<0.001; figure 1B).  240 
3. Granular Cell Layer Volume  241 
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At PD2, the three groups of TS mice presented smaller volumes of the GCL than the 242 
three groups of controls (‘karyotype’: P=0.012; figures 1C and 1D). Oleic acid 243 
treatment increased the GCL volume in pups of both karyotypes (TS-OA vs. TS-V, 244 
P<0.05, CO-OA vs. CO-V, P<0.05), while prenatal linolenic acid administration only 245 
enhanced the GCL volume of CO mice with respect to the CO-V group (P<0.05; 246 
figures 1C and 1D). 247 
4. BrdU Immunohistochemistry 248 
At PD2, TS-V mice presented a lower number of BrdU+ cells per slice (P<0.01, figures 249 
2A and 2B), and a lower total number of cells than their CO-V littermates (P<0.01; 250 
figure 2C). Both prenatal treatments increased the number of BrdU+ cells per slice in 251 
TS pups (TS-OA vs. TS-V: P<0.001; TS-LNA vs. TS-V: P<0.01; figure 2B), and the 252 
total number of BrdU+ cells (TS-OA vs. TS-V: P<0.01; TS-LNA vs. TS-V: P<0.01; 253 
figure 2C). However, neither the density nor the total number of this population of cells 254 
were significantly modified by any of the treatments in PD2 CO mice. 255 
5. Mature Granule Cell Count (DAPI Staining) 256 
TS-V mice presented a lower total number of DAPI+ cells than their CO-V littermates 257 
(P<0.05; figures 2D and 2F), although the density of this population of cells did not 258 
significantly differ between PD2 pups of both karyotypes (figure 2E). In TS mice, oleic 259 
acid treatment increased the density (TS-OA vs. TS-V: P<0.05; figure 2E) and the total 260 
number of DAPI+ cells (TS-OA vs. TS-V P<0.01; figure 2F), and both treatments 261 
significantly increased the total number of this population of cells in CO animals (CO-262 
OA vs. CO-V P<0.05; CO-LNA vs. CO-V: P<0.05; figure 2F).  263 
Long-term Effects of Prenatal Treatment 264 
1. Histology  265 
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At PD45, TS-V mice presented a lower density (P<0.01; Supplemental figure 1B), 266 
and a lower total number of Ki67+ (P<0.01; Supplemental figure 1C) and BrdU+ 267 
(P<0.05; Supplemental figure 1E) cells than their CO-V littermates. Prenatal 268 
treatment with oleic or linolenic acid did not exert any long-term effect on the GCL 269 
volume, the density, or the total number of Ki67+ or of BrdU+ cells in TS mice, since 270 
neither TS-OA nor TS-LNA mice differed in any of these measurements from TS-V 271 
mice (Supplemental figures 1A-1E). However, at PD45, TS-LNA mice showed a 272 
higher density of mature DAPI+ cells than TS-V mice (P<0.05; Supplemental figure 273 
1F).  274 
At PD45, TS-V mice presented a smaller number of PSD95+ puncta than their CO-V 275 
littermates in all hippocampal areas analyzed (CA1: P<0.05; CA3: P<0.05; ML: P<0.01; 276 
figures 3A and 3B). Prenatal treatment with oleic acid produced a long-term 277 
enhancement of the number of PSD95+ puncta in TS mice (TS-OA vs. TS-V: CA1: 278 
P<0.05; CA3: P<0.01; ML: P<0.05); while treatment with linolenic acid increased the 279 
number of PSD95+ puncta in the ML of TS-LNA mice with respect to TS-V animals, 280 
although no changes were observed in the other hippocampal areas analyzed (CA1: 281 
P=0.65; CA3: P=0.14; ML: P<0.05). 282 
Although TS-V mice presented a smaller number of SYN+ puncta than CO-V mice in 283 
CA1 (P<0.05), CA3 (P<0.01) and in the ML (P<0.01; figures 3C and 3D), none of the 284 
treatments modified the number of SYN+ puncta in TS or CO mice. 285 
 286 
2. Cognition:  Morris Water Maze 287 
2.1. Reference learning and Memory 288 
The six groups of mice reduced their latency to reach the platform when all sessions 289 
were taken into account (session 1-12: RM ANOVA ‘session’: P<0.001; figure 4A), 290 
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both in the sessions in which the platform position was changed daily (sessions 1-8: 291 
P<0.001) and in those in which the platform position was kept constant (sessions 9-12: 292 
P<0.001). 293 
The reduction in latency between sessions significantly differed between animals of 294 
both karyotypes (‘session x karyotype’: P<0.001) and of the three treatment conditions 295 
(‘session x treatment’: P=0.001). 296 
When each pair of learning curves was analyzed separately, TS-V mice presented a 297 
deteriorated performance when compared to their CO-V littermates (P<0.001; figure 298 
4B). 299 
TS-OA (sessions 1-12: P=0.006; sessions 1-8: P=0.018; sessions: 9-12: P=0.026; 300 
figure 4C), and TS-LNA mice showed lower latencies to reach the platform than TS-V 301 
animals (sessions 1-12: P=0.007; sessions 1-8: P=0.020; sessions 9:12: P=0.059; 302 
figure 4E).  303 
In the case of the CO animals, prenatal administration of oleic acid did not modify their 304 
performance in the MWM, since CO-OA mice did not differ in their latency to reach the 305 
platform when compared with CO-V mice (sessions 1-12: P=0.11; sessions 1-8: 306 
P=0.30; sessions 9-12: P=0.060; figure 4D). CO-LNA animals presented lower 307 
latencies to reach the platform than the CO-V group only in the sessions in which the 308 
platform position was kept constant (Sessions 1-12: P=0.23; sessions 1-8: P=0.37; 309 
sessions 9-12: P=0.043; figure 4F).  310 
2.2. Working Memory 311 
When all the groups of mice were analyzed together, statistical analyses demonstrated 312 
a marked reduction in their latency to reach the platform across trials (RM ANOVA 313 
‘trial’: P<0.001; figure 5A). However, the reduction in these latencies differed between 314 
the three groups of TS and the three groups of CO mice (‘trial x karyotype’: P<0.001), 315 
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and between TS and CO mice under the three treatment conditions (‘trial x treatment’: 316 
P=0.037). 317 
When each pair of learning curves was analyzed separately, it was observed that TS-V 318 
animals showed a deteriorated working memory, since they did not reduce their latency 319 
to reach the platform throughout the trials (P=0.82; figure 5B), and their latency to 320 
reach the platform was higher than that of CO-V mice (P=0.001, figure 5B). However, 321 
TS-OA (RM ANOVA ‘trial’: P=0.012, figure 5C) and TS-LNA mice (P=0.052; figure 5E) 322 
reduced their latency to reach the platform between trials, indicative of their ability to 323 
learn the platform position across trials.  324 
In euploid mice, both groups of mice, CO-OA (‘trial’: P<0.001; figure 5D) and CO-LNA 325 
(P<0.001; figure 5F) reduced their latency to reach the platform between trials. 326 
2.3. Cued Sessions 327 
TS and CO mice under the different treatments did not differ in their latency to reach 328 
the platform during the cued sessions when the platform was visible (‘karyotype’: 329 
P=0.14, ‘treatment: P=0.30; karyotype x treatment’: P=0.038; data not shown).  330 
2.4. Spatial Memory  331 
During the probe trial, TS-V mice crossed fewer times over the place where the 332 
platform was placed during the training sessions (P<0.05; figure 6A) and entered the 333 
trained quadrant fewer times (P<0.05; figure 6B) than their CO-V littermates. 334 
Prenatal treatment with oleic acid or linolenic acid increased the number of crossings 335 
that TS mice performed over the platform position with respect to vehicle-treated 336 
trisomic animals (TS-OA vs. TS-V: P=0.05; TS-LNA vs. TS-V: P<0.05; figure 6A), but 337 
did not exert any significant effect on the number of entries that TS or CO mice made 338 
into the trained quadrant (figure 6B). 339 
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TS-V mice did not show a preference for any of the quadrants (P=0.54; figures 6C and 340 
6E). However, prenatal oleic acid or linolenic acid treatment improved the spatial 341 
memory of TS mice, since TS-OA and TS-LNA animals spent more time in the trained 342 
quadrant than in the rest of the quadrants (TS-OA: P<0.001; TS-LNA: P<0.001; figures 343 
6C and 6E). The three groups of CO mice spent a higher percentage of time in the 344 
trained quadrant than in the rest of the quadrants (CO-OA: P<0.001; CO-LNA: 345 





In this study, prenatal administration of oleic acid and linolenic acid rescued several 349 
neuromorphological alterations found in newborn TS mice. In particular, these 350 
treatments increased their brain weight, the volume of their GCL, and the number of 351 
proliferating and mature granule cells in their hippocampi. When the effects of these 352 
treatments were analyzed six weeks after the discontinuation of the treatment, no 353 
significant effects were found in the volume of the GCL, the number and density of 354 
Ki67+ or BrdU+ cells or the number of SYN+ puncta found in the hippocampus of TS 355 
mice. However, both treatments increased the number of PSD95+ puncta. When the 356 
long-term functional effects of both prenatal treatments were analyzed, TS mice that 357 
received oleic acid or linolenic acid showed improved reference, working, and spatial 358 
memory in the Morris water maze. 359 
Both oleic acid and linolenic acid have been demonstrated to cross the placental and 360 
blood-brain barrier (35, 47, 63). In this study, the pups of the dams treated with these 361 
acids presented an increased level of both acids in plasma. Thus, oleic acid and 362 
linolenic acid were adequately transferred to the pups, incorporated into the 363 
bloodstream and distributed throughout the organism. 364 
Consistent with the altered prenatal neurodevelopment of TS mice and DS individuals 365 
(2, 3, 10, 11, 14, 21, 64), we found that TS mice presented reduced brain weight, GCL 366 
volume, cell proliferation and density of mature cells. Both lipid composition and fatty 367 
acid metabolism are essential for proper neurodevelopment. DS individuals present 368 
lower levels of monounsaturated fatty acids, especially of oleic acid, in their brains (52, 369 
65).  Thus, these deficiencies could play an essential role in the neurodevelopmental 370 
alterations and/or in the functional anomalies found in DS. However, there is increasing 371 
evidence that brain development is not only affected by the total levels of fatty acids, 372 
but also by the ratio and the relationship between these acids. In DS, corn oil that is a 373 
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source of linoleic acid, a precursor of PUFAs of the omega-6 series, which produces 374 
arachidonic acid (ARA), improves brain development (66), supporting the idea of the 375 
essential role of omega-6 and ARA in neurodevelopment. Furthermore, DS brains 376 
present an increased ratio of PUFAs of the omega-3 series with respect to those of the 377 
omega-6 series (65). These authors proposed that this ratio was modified due to the 378 
decrease in ARA brains and that this effect plays a role in the alterations in 379 
neurodevelopment found in in DS. Therefore, in the present study it is possible that 380 
adding omega-3 PUFAS to the diet induced a reduction in ARA levels, thereby 381 
increasing the total amount of omega-3 fatty acids and enhancing the omega-3: 382 
omega-6 ratio. This effect could be partially responsible for the benefits found after its 383 
administration.  384 
 385 
In the present study, prenatal administration of oleic and linolenic acid increased cell 386 
proliferation in the hippocampi of TS pups and reduced the hypocellularity in this 387 
structure. There is evidence of the pro-neurogenic effect of both acids in different 388 
conditions (25, 32-34, 47, 48, 66). Prenatal administration of compounds that increase 389 
neurogenesis, such as the serotonin reuptake inhibitor Fluoxetine, normalizes the 390 
neuroanatomical anomalies in TS mice (11). Thus, the increase in granule cell density 391 
induced by these compounds could be due to the enhanced cell proliferation, 392 
differentiation, and/or survival.  393 
During neurodevelopment, the primary role of oleic acid in neurogenesis is to act as a 394 
neurotrophic factor (26, 27). During this period, brain development is regulated by the 395 
Alpha-Fetoprotein (AFP)/albumin ratio that modulates the neurotrophic effects of oleic 396 
acid (67). Thus, the balance between these two signals seems to be essential to 397 
induce neurogenesis in embryonic development, while its imbalance contributes to the 398 
onset of several alterations during neurodevelopment. DS individuals present a 399 
reduction in the serum levels of AFP and albumin (68, 69) that correlates with a lower 400 
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concentration of oleic acid in the brain (65). Thus, it is possible, that after the 401 
administration of oleic acid during the prenatal stages, adequate levels of this fatty acid 402 
were reached, thereby correcting the alterations in hippocampal neurogenesis in TS 403 
mice. However, after discontinuation of the treatment, these levels would likely have 404 
returned to their original altered states, and this might be one of the reasons why the 405 
beneficial effects of oleic and linolenic acid on neurogenesis in TS mice are not seen 406 
one month later. 407 
Regarding linolenic acid, it has been demonstrated that during gestation and in the first 408 
stages of postnatal life an adequate intake of omega-3 fatty acids, such as linolenic 409 
acid, is necessary to allow for the correct development of the brain and neurogenesis 410 
(32). Most of the beneficial effects of omega-3 fatty acids are due to their conversion 411 
into DHA. Numerous studies have demonstrated that the administration of a diet rich in 412 
linolenic acid promotes hippocampal neurogenesis (33, 34, 70). In contrast, DHA 413 
deficiency during gestation, due to the reduced intake of linolenic acid, alters brain 414 
morphology, including the cortical and hippocampal areas, as well as hippocampal 415 
neurogenesis (32). These authors suggest that the inhibition of neurogenesis which 416 
occurs after linolenic acid restriction during gestation could be due to a delay in the cell 417 
cycle or the onset of neurogenesis. In TS mice, alterations in neurogenesis during 418 
prenatal stages are also due to a slowing-down of the cell cycle (1, 10, 14). Thus, the 419 
administration of linolenic acid to pregnant TS females could accelerate the speed 420 
and/or reduce alterations in the cell cycle, increasing the number of neuronal 421 
precursors in TS pups.  422 
Oleic and linolenic acid treatment also enhanced the number of mature granular cells, 423 
possibly due to the well-known effect of both acids on neuronal differentiation and 424 
survival (30, 70-72). This increased cellularity is likely to be responsible for the increase 425 
in the GCL volume and brain weight found in TS mice after prenatal oleic and linolenic 426 
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acid treatment. Linolenic acid treatment increases hippocampal volume (47, 72). 427 
Conversely, restriction of linolenic acid in the diet during gestation alters the normal 428 
development of the brain (32). Because low levels of fatty acids are found in DS brains 429 
(52, 65), their exogenous administration to pregnant TS mice could positively impact 430 
prenatal brain development, restoring the size of the hippocampal structures in their 431 
progeny.  432 
However, most of the beneficial effects of the prenatal administration of oleic and 433 
linolenic acid on the neuromorphological alterations found in TS mice were not 434 
maintained six weeks after the discontinuation of the treatment. These results indicate 435 
that the presence of oleic acid and linolenic acid may be necessary to induce their 436 
proliferative and pro-survival effects in TS mice.  437 
Administration of fatty acids during adulthood also reduces the neuropathology found in 438 
TS mice. Giacomini et al. (66) showed that treatment with corn oil, which contains both 439 
oleic and linoleic acid, rescued brain weight, neurogenesis, dendritogenesis and 440 
cognition in adult TS mice. In addition, using cultures of neural progenitor cells (NPCs) 441 
obtained from DS individuals, they demonstrated that both linolenic and oleic acid can 442 
increase the proliferation rate of NPCs (66).  443 
One of the most relevant results of this study is the finding that prenatal administration 444 
of oleic and linolenic acid produced long-term enhancement of the cognitive abilities of 445 
TS mice in the MWM. Those animals that received this treatment during gestation 446 
demonstrated better reference, working, and spatial memory than the ones that 447 
received the vehicle, as indicated by their reduced latency to reach the platform across 448 
sessions (reference memory), and across trials in each session (working memory). 449 
Finally, both treatments also increased the memory of the platform position in TS mice, 450 
since these animals spent more time searching for the platform position in the trained 451 
quadrant and crossed over the platform position more times than the vehicle-treated 452 
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TS mice. These results agree with the literature that reports the pro-cognitive effects of 453 
oleic and linolenic acid and their derivatives. DHA supplementation improves cognition 454 
and spatial memory in normal rodents, in murine models of Alzheimer’s disease (AD), 455 
(49, 50) and in the pups of rats supplemented with linolenic acid during gestation (51). 456 
Moreover, administration of corn oil to adult TS mice also induces pro-cognitive effects 457 
(66), and treatment with a diet supplemented with fish oil that contained linolenic acid 458 
rescued cognitive deficits in mice that overexpressed the RCAN-1 gene which is 459 
triplicated in DS and in TS mice (73). 460 
The pro-cognitive effects found in this study cannot be attributed to changes in 461 
neurogenesis. However, changes in the characteristics of the synaptic connections 462 
might be partially responsible for these beneficial effects in the cognitive abilities of TS 463 
mice. 464 
Although the total number of synapses was unchanged after both treatments, as 465 
demonstrated by the similar number of SYN+ puncta found in TS mice under all 466 
treatments, oleic acid administration increased the number of PSD95+ puncta, a 467 
postsynaptic marker of excitatory synapses (74, 75), in all hippocampal areas 468 
analyzed. Linolenic acid treatment only increased PSD95+ in the ML of the 469 
hippocampus. Since the number of synapses was similar in all groups, these results 470 
suggest that the altered inhibitory-excitatory balance of TS mice could have been 471 
partially corrected. The over-inhibition, due to enhanced GABAergic transmission and 472 
reduced glutamatergic transmission, characteristic of TS mice, has been proposed to 473 
play an essential role in the cognitive difficulties of TS mice (76). Among the 474 
mechanisms proposed as being responsible for the beneficial effects of oleic and 475 
linolenic is the increase in glutamatergic transmission, through the increased 476 
expression of vesicular glutamate transporters 1 and 2 (VGluT1 and VGluT2) (33, 71, 477 
72). Oleic acid promotes the synthesis of the post-synaptic protein PSD95 (30), which 478 
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is implicated in Long-Term Potentiation (LTP) generation (77). Thus, an increase in 479 
excitatory transmission could be partially responsible for the long-term benefits exerted 480 
by oleic acid and linolenic acid in the reference memory, working memory, and spatial 481 
memory of TS mice found in this study. 482 
In conclusion, prenatal administration of oleic and linolenic acid restored several 483 
neuromorphological alterations in the TS65Dn mouse model of DS. In addition, they 484 
produced long-term enhancement of the cognitive abilities of these animals, possibly 485 
by normalizing the excitatory-inhibitory synaptic balance. These results provide 486 
evidence for the potential therapeutic effect of oleic and linolenic acid in DS. Given that 487 
both are natural substances present in the human diet, they could be administered 488 
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Figure 1. Body (A) and Brain (B) weights, and GCL Volume (C) of PD2 TS and CO 
mice prenatally treated with oleic acid, linolenic acid, or vehicle. Representative 
microscopy sections of Nissl staining in the hippocampus of the six groups of 
mice (D). Values in A, B and C are means ± SEMs, n=6-7 per group. Labeled bars 
without a common letter differ by P < 0.05, by Fisher’s LSD post-hoc tests Scale bar in 
D: 200 μm.  
Figure 2. Representative confocal images of BrdU+ immunohistochemistry (A) 
and by DAPI staining (D), number of BrdU+ cells per slice (B), the total number 
(C) of BrdU+ cells, and of the density (E) and total number (F) of DAPI+ cells in 
the hippocampus of TS and CO pups prenatally treated with oleic acid, linolenic 
acid, or vehicle. Scale bar in A: 100 μm, Scale bar in D: 5 μm. Values in B, C, E and F 
are means ± SEMs, n=6-7 per group. Labeled bars without a common letter differ by P 
< 0.05, by Fisher’s LSD post-hoc tests. 
Figure 3. Representative confocal images PSD95 (A), and SYN (C) 
immunochemistry in the hippocampus, number of PSD95+ (B), and SYN+ (D) 
puncta in the CA1, CA3 areas and ML of the hippocampus of 45-days-old TS and 
CO mice that received oleic acid, linolenic acid, or vehicle prenatally. Scale bars 
in A and C: 5 μm. Values in B and D are means ± SEMs, n=6-7 per group. Labeled 
bars without a common letter differ by P < 0.05, by Fisher’s LSD post-hoc tests. 
Figure 4. Latency to reach the platform during the twelve acquisition sessions in 
the MWM exhibited between PD30 and PD45 by all groups of mice (A), by TS-V 
and CO-V mice (B), by TS-OA and TS-V mice (C), by CO-OA and CO-V mice (D), 
by TS-LNA and TS-V mice (E), and by CO-LNA and CO-V mice (F). Values are 
means ± SEMs, n=10-13 per group. *: p<0.05, **: p<0.01, ***: p<0.001 vs. CO-V (in B, 
40 
 
D and F) or vs. TS-V (in C and E), Fisher’s LSD post-hoc tests. On the right side of 
each figure, the P-value of the difference between both learning curves across the 
twelve sessions (RM ANOVAs) is shown. On top of each figure, the P values of the 
differences between the learning curves of the different groups of mice during the first 8 
and the last 4 sessions are shown. 
Figure 5. Latency to reach the platform during each trial of the first eight 
acquisition sessions exhibited between PD30 and PD45 by all animals (A), by TS-
V and CO-V mice (B), by TS-OA and TS-V mice (C), by CO-OA and CO-V mice (D), 
by TS-LNA and TS-V mice (E), and by CO-LNA and CO-V mice (F), in the MWM. 
Values are means ± SEMs, n=10-13 per group. *: p<0.05, **: p<0.01, ***: p<0.001, vs. 
CO-V (in B, D and F) or vs. TS-V (in C and E) Fisher’s LSD post-hoc tests. On the right 
side of each figure, the P-value of the main effects for ‘karyotype’ (figure B), or 
‘treatment’: (figures C-F) after RM ANOVAs, are shown. The dotted lines and the P-
values beside them represent the significance of the change in latency across the trials 
(RM ANOVA ‘trial’ of each learning curve). 
Figure 6. Number of crossings over the platform position (A) and Number of 
entries in the trained quadrant (B) performed at PD45 in the probe trial by TS and 
CO mice prenatally treated with oleic acid, linolenic acid, or vehicle; Percentage 
of time spent in each quadrant during the probe trial by TS-OA, TS-LNA, and TS-
V (C), and CO-OA, CO-LNA, and CO-V animals (D), and Percentage of time spent 
in the trained quadrant vs. the rest of the quadrants by TS-OA, TS-LNA, and TS-V 
(E), and CO-OA, CO-LNA, and CO-V (F) mice. Values are means ± SEMs, n=10-13 
per group. Labeled bars without a common letter differ by P < 0.05, by Fisher’s LSD 
post-hoc tests. ***: p<0.001 trained quadrant vs. the rest of the quadrants, Fisher’s 
LSD post-hoc tests. The dotted lines in figures C-F represent the chance level, i.e. a 
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Supplementary figure 1. GCL volume (A); density (B) and total number (C) of 
Ki67+ cells; density (D) and total number (E) of BrdU+ cells; density (F) and total 
number of DAPI-stained cells in the hippocampus of 45 days-old TS and CO 
animals that received oleic acid, linolenic acid, or vehicle during gestation. 
Values are means ± S.E.M.s, n=6-7. Labeled bars without a common letter differ by 
P<0.05. Fisher’s LSD post-hoc tests. 
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